Weranja Ranasinghe1, Brian F Chapin1, Isaac Yi Kim2, Prasanna Sooriakumaran3, Nathan Lawrentschuk4,5,6. 1. MD Anderson Cancer Centre, University of Texas, Houston, TX, USA. 2. Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA. 3. University College London Hospital, London, UK. 4. Department of Surgery, University of Melbourne and Olivia Newton-John Cancer Centre, Austin Hospital, Melbourne, Australia. 5. EJ Whitten Prostate Cancer Research Centre at Epworth Healthcare, Melbourne, Australia. 6. Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia.
Abstract
OBJECTIVE: To review the ongoing randomised trials of cytoreductive prostatectomy (CRP) in de novo hormone-sensitive metastatic prostate cancer (HSPC) in order to identify their goals and assess their strengths and weaknesses. METHODS: PubMed, MEDLINE and clinical trials websites searches were performed to identify currently ongoing trials of CRP in de novo HSPC. RESULTS: Nine randomised clinical trials in CRP were identified and included: Southwest Oncology Group (SWOG) 1802, Surgery in Metastatic Carcinoma of Prostate (SIMCAP), Adjuvant Treatments to the Local Tumour for Metastatic Prostate Cancer: Assessment of Novel Treatment Algorithms (IP2-ATLANTA), Testing Radical prostatectomy in men with prostate cancer and oligoMetastases to the bone (TRoMbone), Impact of Radical Prostatectomy as Primary Treatment in Patients with Prostate Cancer with Limited Bone Metastases (g-RAMPP), Cytoreductive Prostatectomy vs Cytoreductive Prostate Irradiation as a Local Treatment Option for Metastatic Prostate Cancer: a Multicentric Feasibility Trial (LoMP II), Androgen-Deprivation Therapy or Androgen-Deprivation Therapy Plus Definitive Treatment (Radiation or Surgery) (FUSCC-OMPCa), and the Testing Radical Prostatectomy in Chinese Men with Prostate Cancer and oligoMetastases to the Bone study. Each study was different; assessing various primary outcome measures including overall survival (OS), progression-free survival and feasibility to randomise between standard therapy and CRP or between radiation therapy and CRP in the metastatic setting. In the oligometastatic setting, the trials assess OS, feasibility to randomise and time to castration resistance. Similarly, a number of secondary endpoints ranging from cancer-specific outcomes to quality-of-life outcomes are being investigated. The inclusion criteria in these trials also varied in terms of volume of metastatic disease (oligometastatic to high-volume metastatic disease), diagnosis of metastases (imaging based vs biopsy confirmed), imaging modalities used (conventional to newer modalities), as well as outcomes and follow-up regimes. CONCLUSION: While there are differences in each protocol, each trial aims to address different aspects of CRP in de novo HSPC. Therefore, the specific goals of each study and the limitations have to be taken into consideration when interpreting the results of these trials.
OBJECTIVE: To review the ongoing randomised trials of cytoreductive prostatectomy (CRP) in de novo hormone-sensitive metastatic prostate cancer (HSPC) in order to identify their goals and assess their strengths and weaknesses. METHODS: PubMed, MEDLINE and clinical trials websites searches were performed to identify currently ongoing trials of CRP in de novo HSPC. RESULTS: Nine randomised clinical trials in CRP were identified and included: Southwest Oncology Group (SWOG) 1802, Surgery in Metastatic Carcinoma of Prostate (SIMCAP), Adjuvant Treatments to the Local Tumour for Metastatic Prostate Cancer: Assessment of Novel Treatment Algorithms (IP2-ATLANTA), Testing Radical prostatectomy in men with prostate cancer and oligoMetastases to the bone (TRoMbone), Impact of Radical Prostatectomy as Primary Treatment in Patients with Prostate Cancer with Limited Bone Metastases (g-RAMPP), Cytoreductive Prostatectomy vs Cytoreductive Prostate Irradiation as a Local Treatment Option for Metastatic Prostate Cancer: a Multicentric Feasibility Trial (LoMP II), Androgen-Deprivation Therapy or Androgen-Deprivation Therapy Plus Definitive Treatment (Radiation or Surgery) (FUSCC-OMPCa), and the Testing Radical Prostatectomy in Chinese Men with Prostate Cancer and oligoMetastases to the Bone study. Each study was different; assessing various primary outcome measures including overall survival (OS), progression-free survival and feasibility to randomise between standard therapy and CRP or between radiation therapy and CRP in the metastatic setting. In the oligometastatic setting, the trials assess OS, feasibility to randomise and time to castration resistance. Similarly, a number of secondary endpoints ranging from cancer-specific outcomes to quality-of-life outcomes are being investigated. The inclusion criteria in these trials also varied in terms of volume of metastatic disease (oligometastatic to high-volume metastatic disease), diagnosis of metastases (imaging based vs biopsy confirmed), imaging modalities used (conventional to newer modalities), as well as outcomes and follow-up regimes. CONCLUSION: While there are differences in each protocol, each trial aims to address different aspects of CRP in de novo HSPC. Therefore, the specific goals of each study and the limitations have to be taken into consideration when interpreting the results of these trials.
Authors: Benjamin J Lichtbroun; Arnav Srivastava; Sai Krishnaraya Doppalapudi; Kevin Chua; Eric A Singer Journal: Cancers (Basel) Date: 2022-05-27 Impact factor: 6.575
Authors: Isaac E Kim; Thomas L Jang; Sinae Kim; David Y Lee; Daniel D Kim; Eric A Singer; Saum Ghodoussipour; Mark N Stein; Monish Aron; Marc A Dall'Era; Isaac Yi Kim Journal: Cancer Med Date: 2021-10-29 Impact factor: 4.452
Authors: Isaac Yi Kim; Antonina Mitrofanova; Sukanya Panja; Joshua Sterling; Arnav Srivastava; Juliana Kim; Sinae Kim; Eric A Singer; Thomas L Jang; Saum Ghodoussipour; Biren Saraiya; Tina Mayer; Hatem E Sabaawy; Bertram Yuh; Seok Soo Byun; Wun-Jae Kim; Shigeo Horie Journal: Prostate Int Date: 2022-03-09
Authors: Nicolaas Lumen; Elise De Bleser; Sarah Buelens; Wesley Verla; Filip Poelaert; Wietse Claeys; Valérie Fonteyne; Sofie Verbeke; Geert Villeirs; Kathia De Man; Sylvie Rottey; Charles Van Praet; Karel Decaestecker; Piet Ost Journal: Eur Urol Open Sci Date: 2021-06-05